卡维地洛联合缬沙坦治疗慢性心力衰竭的效果及对患者心功能和脑钠肽水平的影响  

Clinical efficacy of carvedilol combined with valsartan in the treatment of chronic heart failure and its influence on cardiac function and brain natriuretic peptide

作　　者：王大强[1] 韩永建 孙丹 Wang Daqiang;Han Yongjian;Sun Dan(Department of Cardiology,First Affiliated Hospital of Nanyang Medical College,Nanyang 473000,China)

机构地区：[1]南阳医学高等专科学校第一附属医院心血管内科,河南省473000

出　　处：《中国实用医刊》2021年第18期93-96,共4页Chinese Journal of Practical Medicine

摘　　要：目的探讨卡维地洛联合缬沙坦治疗慢性心力衰竭的临床效果及对患者心功能和脑钠肽水平的影响。方法回顾性纳入2019年1月至2020年12月南阳医学高等专科学校第一附属医院收治的慢性心力衰竭患者158例。根据治疗用药不同分为缬沙坦组和联合组,每组79例。比较两组患者治疗6个月的临床治疗效果,治疗前和治疗6个月心功能指标变化、血浆脑钠肽(BNP)水平变化、炎症指标变化、不良反应发生率。结果治疗6个月,联合组患者临床治疗总有效率(97.47%)高于缬沙坦组(87.34%),P<0.05。维地洛联合缬沙坦治组患者不良反应发生率(12.66%)高于缬沙坦组(8.86%),但P>0.05。治疗6个月,联合组患者左室射血分数(LVEF)、心搏出量(SV)高于缬沙坦组,左心室舒张末内径(LVEDD)、左心室收缩末内径(LVESD)低于缬沙坦组(P<0.05)。治疗6个月,联合组患者BNP、炎症指标C-反应蛋白(CRP)、白细胞介素-6(IL-6)水平低于缬沙坦组(P<0.05)。结论与单用缬沙坦治疗比较,卡维地洛联合缬沙坦治疗慢性心力衰竭具有更好的临床疗效,安全性较高。Objective To study the clinical efficacy of carvedilol combined with valsartan in the treatment of chronic heart failure and its influence on cardiac function and brain natriuretic peptide.Methods A total of 158 patients with chronic heart failure treated in the First Affiliated Hospital of Nanyang Medical College from January 2019 to December 2020 were retrospectively included.According to different treatment drugs,they were divided into valsartan group and joint group,with 79 cases in each group.The clinical therapeutic effects,changes of cardiac function indexes,changes of plasma brain natriuretic peptide(BNP)and inflammatory indexes before and after 6 months of treatment,and incidence of adverse reactions were compared between the two groups.Results After 6 months of treatment,the total effective rate of the joint group(97.47%)was higher than that of valsartan(87.34%),P<0.05.The incidence of adverse reactions in the group treated with vadilol combined with valsartan(12.66%)was higher than that in the group treated with valsartan(8.86%),but P>0.05.After 6 months of treatment,the left ventricular ejection fraction(LVEF)and Stroke volume(SV)in joint group were higher than those in valsartan group,and the left ventricular end diastolic diameter(LVEDD)and left ventricular end systolic diameter(LVESD)were lower than those in valsartan group(P<0.05).After 6 months of treatment,the levels of plasma BNP,inflammatory index C-reactive protein(CRP)and interleukin-6(IL-6)in carvedilol combined with valsartan group were lower than those in valsartan group(P<0.05).Conclusions Compared with valsartan alone,carvedilol combined with valsartan has better clinical efficacy and safety in the treatment of chronic heart failure.

关 键 词：脑钠肽 卡维地洛 缬沙坦 慢性心力衰竭 心功能 

分 类 号：R541.6[医药卫生—心血管疾病]